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Escape from peripheral tolerance checkpoints that
control cytotoxic CD8+ T cells is important for cancer
immunotherapy and autoimmunity, but pathways en-
forcing these checkpoints are mostly uncharted. We
reveal that the HECT-type ubiquitin ligase activator,
NDFIP1, enforces a cell-intrinsic CD8+ T cell check-
point that desensitizes TCR signaling during in vivo
exposure to high antigen levels. Ndfip1-deficient
OT-I CD8+ T cells responding to high exogenous tol-
erogenic antigen doses that normally induce anergy
aberrantly expanded and differentiated into effector
cells that could precipitate autoimmune diabetes in
RIP-OVAhi mice. In contrast, NDFIP1 was dispens-
able for peripheral deletion to low-dose exogenous
or pancreatic islet-derived antigen and had little
impact upon effector responses to Listeria or acute
LCMV infection. These data provide evidence that
NDFIP1mediates a CD8+ T cell tolerance checkpoint,
with a different mechanism to CD4+ T cells, and indi-
cates that CD8+ T cell deletion and anergy aremolec-
ularly separable checkpoints.
INTRODUCTION
Activated CD8+ T lymphocytes are key effector cells of the adap-
tive immune system that produce inflammatory cytokines and
lytic granule proteins to kill infected or neoplastic cells. However,
potentially pathogenic self-reactive CD8+ T cells escape thymic
selection, and peripheral tolerance checkpoints have thus
evolved to control these cells and to enable tolerance to food,This is an open access article under the CC BY-Ncommensal microbiota, and fetal antigens. These peripheral
checkpoints must respond to a range of antigen levels because
of variation in antigen amount released by different tissues.
Malignant cancer cells can exploit these checkpoints to prevent
immune recognition of mutated neo-antigens, and checkpoint
inhibitors have emerged as a third pillar of cancer treatment
alongside chemotherapy and radiotherapy.
Peripheral CD8+ T cells undergo deletion or anergy when
resting naive T cells encounter antigen in the absence of infection
or inflammation. In this context, the responding T cells do not
become cytotoxic effectors and adopt a transcriptional profile
that is distinct from other differentiation states (Hernandez
et al., 2001; Parish et al., 2009). CD8+ T cell deletion occurs
when cells undergo BIM-dependent apoptosis but largely retain
T cell receptor (TCR) signaling capacity (Davey et al., 2002;
Parish et al., 2009; Redmond et al., 2005; Wagle and Parish,
2016), whereas CD8+ T cell anergy is characterized by persis-
tence of cells with diminished TCR signaling, with tolerogenic an-
tigen levels thought to determine outcome (Redmond et al.,
2005). The molecular pathways that enforce CD8+ T cell anergy
in vivo are poorly defined, and it is unknown whether anergy
checkpoint disruption interferes with CD8+ T cell deletion or if
the two processes are molecularly distinct.
NDFIP1, a Golgi and intracellular vesicle localized transmem-
brane protein, plays a selective checkpoint role within CD4+
T cells (Altin et al., 2014; Oliver et al., 2006). NDFIP1 binds to
and activates HECT-type E3 ubiquitin ligases (Mund and Pel-
ham, 2009; Riling et al., 2015), thereby triggering ubiquitin-medi-
ated degradation of key T cell differentiation regulators, including
JUNB, RORgt, and JAK1 (Layman et al., 2017b; O’Leary et al.,
2016; Oliver et al., 2006). In T cells, NDFIP1 primarily recruits
and activates the HECT-type E3 ligase ITCH (Oliver et al.,
2006). Ndfip1-deficient CD4+ T cells resist both in vitro anti-
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levels because of excessive interleukin (IL)-2 production, a fail-
ure to exit the cell cycle, and aberrant differentiation into T helper
(Th) 2 or Th17 cells (Altin et al., 2014; Layman et al., 2017b; Oliver
et al., 2006; Ramos-Hernández et al., 2013). Mice lacking
NDFIP1 develop a fatal T cell-mediated inflammatory disease
associated with T cell activation, regulatory T cell dysfunction,
and Th2-mediated organ pathology (Altin et al., 2014; Beal
et al., 2011; Layman et al., 2017a; Oliver et al., 2006). NDFIP1
likely plays similar roles in humans, because NDFIP1 polymor-
phisms and ITCH deficiency are associated with inflammatory
and autoimmune diseases (Ferreira et al., 2011; Franke et al.,
2010; Hu et al., 2011; International Multiple Sclerosis Genetics
et al., 2011; Lohr et al., 2010; Ramon et al., 2011).
Despite elevated activated effector CD8+ T cells in Ndfip1/
mice and high Ndfip1 expression in CD8+ T cells (Altin et al.,
2014), CD8+ T cell activation in Ndfip1/ mice is largely an indi-
rect consequence of excessive IL-4 production by Ndfip1
mutant CD4+ T cells (Altin et al., 2014; Kurzweil et al., 2014).
However, excessive bystander inflammation in Ndfip1/ mice
may mask a CD8+ T cell-intrinsic role for NDFIP1. Here we
circumvent these complications by transferring Ndfip1 mutant
and wild-type OT-I TCR transgenic CD8+ T cells and tracing their
response. We reveal that NDFIP1 is a critical checkpoint against
CD8+ T cell expansion and effector formation during chronic
exposure to high tolerogenic antigen levels.
RESULTS
Ndfip1 Is Dispensable for CD8+ T Cell Deletional
Tolerance to a Pancreatic Self-Antigen
Bystander CD8+ T cell activation confounds analysis of any CD8+
T cell-intrinsic role of NDFIP1 in Ndfip1kru/kru mice homozygous
for an NDFIP1-truncating null mutation (Altin et al., 2014). Acti-
vated or effector CD44hi CD8+ T cell accumulation was reduced
inNdfip1kru/krumice bearing a rearranged TCR transgene encod-
ing OT-I, an ovalbumin (OVA)-specific major histocompatibility
complex class I (MHC class I)-restricted TCR, andwas abolished
in Rag1/OT-INdfip1kru/krumice in which no other TCRs can be
expressed (Figure S1A). Thus, Rag1/ Ndfip1kru/kru OT-I mice
provided a homogeneous source of naive Ndfip1-deficient
CD8+ T cells.
We first tested a peripheral CD8+ T cell deletion checkpoint
triggered by low self-antigen from pancreatic islet b cells,
because NDFIP1 loss disrupts a similar CD4+ T cell checkpoint
(Altin et al., 2014). A 50:50 mix of Ndfip1kru/kru (CD45.1/CD45.2)
and Ndfip1+/+ (CD45.1/CD45.1) Rag1/ OT-I CD8+ T cells was
labeled with the cell division dye Cell Trace Violet (CTV). The cells
were injected into CD45.2/CD45.2 Ndfip1+/+ Rag1+/+ recipients
bearing the rat insulin protein (RIP)-OVAhi transgene or non-
transgenic (B6) controls (Figure S1B). In RIP-OVAhi mice, soluble
OVA expressed in insulin-secreting pancreatic islet b cells is
constitutively cross-presented by dendritic cells in the draining
pancreatic lymph nodes. Transferred OT-I cells divide in
response to cross-presented OVA but do not form cytotoxic
effector cells and undergo BIM-dependent apoptotic death
(Davey et al., 2002; Parish et al., 2009; Wagle and Parish,
2016). However, co-transferred Ndfip1kru/kru and Ndfip1+/+ OT-I
cells proliferated comparably, as assessed by cell ratios,578 Cell Reports 24, 577–584, July 17, 2018numbers, and CTV dilution (Figures S1C–S1E), and failed to
differentiate into effector cells (data not shown) in RIP-OVAhi re-
cipients. RIP-OVAhi mice given either Ndfip1kru/kru or Ndfip1+/+
OT-I cells also did not develop diabetes, with both wild-type
and mutant cells deleted normally by 6 weeks post-transfer (Fig-
ures S1F–S1H). Thus, in contrast to CD4+ T cells, Ndfip1 is
dispensable for a peripheral CD8+ T cell deletion checkpoint to
a tissue-restricted self-antigen.
Ndfip1 Deficiency Disrupts CD8+ T Cell Tolerance to a
Pancreatic Self-Antigen in the Context of Higher-
Antigen Doses
Islet-specific Ndfip1 mutant CD4+ T cells do not cause diabetes
unless simultaneously exposed to a large, systemic bolus of tol-
erogenic antigen (Altin et al., 2014). To test whether a similar
NDFIP1-dependent checkpoint exists in CD8+ T cells, RIP-OVAhi
mice injectedwithNdfip1mutant or wild-typeOT-I cells as in Fig-
ure S1F (day 0) were given either a high dose (10 mg) of OVA pep-
tide (SIINFEKL) or saline (PBS) on days 1, 1, and 2 (Figure 1A).
As in Figure S1G, neither wild-type nor mutant cells caused dia-
betes without peptide treatment (Figure 1B). Peptide-treated
wild-type OT-I cells also did not cause diabetes (Figure 1B).
However, 84% of RIP-OVAhi mice given mutant OT-I cells and
systemic OVA peptide developed diabetes associated with
pancreatic islet infiltration and destruction (Figures 1B and 1C),
with peptide treatment augmentingmutant cell numbers (Figures
1D and 1E). Thus, NDFIP1 cell autonomously restrains effector
CD8+ T cell accumulation and target tissue cell destruction,
but only in response to high systemic tolerogen levels.
Tolerogen Concentration Governs Ndfip1 Restraint of
CD8+ T Cell Expansion and Differentiation
Low tolerogen doses induce peripheral CD8+ T cell deletion,
whereas higher doses cause CD8+ T cell persistence in an aner-
gic state (Redmond et al., 2005). To test whether NDFIP1 is
important for the CD8+ T cell anergy—but not low-dose dele-
tion—checkpoint, we co-transferred a 50:50 mix of CD45-
marked Ndfip1kru/kru and Ndfip1+/+ OT-I cells into wild-type B6
mice as before (day 1) (Figure 2A). Recipient mice were then
given daily intravenous (i.v.) injections of either PBS or a low
(1 mg) or high (10 mg) dose of OVA peptide on days 0, 1, and 2.
The mutant and wild-type OT-I cell numbers increased compa-
rably in the spleen by day 3 after the first peptide injection (Fig-
ures 2B–2D). However, a striking increase inNdfip1kru/kru relative
to Ndfip1+/+ OT-I cells occurred by day 6 after high-dose pep-
tide, with mutant cells making up 86% of cells (Figures 2B–2D).
By contrast, mutant cell ratios and numbers exhibited little differ-
ence at day 6 after low-dose peptide (Figures 2C and 2D). Thus,
NDFIP1 acts cell autonomously to inhibit CD8+ T cell expansion
to high systemic tolerogen levels.
In CD4+ T cells, NDFIP1 promotes cell-cycle exit as measured
by Ki67 loss in T cells responding to low- or high-tolerizing anti-
gen doses (Altin et al., 2014). By contrast, the fraction of Ki67+
OT-I cells induced by high-dose peptide was comparable in
mutant and wild-type cells (Figure 2E). We next measured the
replication rate of responding OT-I cells on days 4 and 5 through
incorporation of the thymidine analog 5-ethynyl-20-deoxyuridine
(EdU), and a higher percentage of Ndfip1kru/kru OT-I cells had
C
A 
D
B 
E
Figure 1. NDFIP1 Limits Autoimmune Pathology after High Antigen
Dose Stimulation
(A) 2 3 106 Ndfip1+/+ or Ndfip1kru/kru OT-I cells were injected into RIP-
OVAhi mice that did or did not receive 10 mg OVA peptide on days 1, 1,
and 2.
(B) Diabetes incidence in the treatment groups (n = 17 mice per group from 2
experiments).
(C) Representative day 9 islet histology sections from peptide- or PBS-treated
RIP-OVAhi mice in (B) that received Ndfip1kru/kru OT-I cells.
(D and E) Representative (D) and pooled data (E) (error bars are SEM)
showing Ndfip1kru/kru OT-I numbers at day 9 in the draining sacral and
pancreatic lymph nodes of peptide-treated RIP-OVAhi versus PBS-treatedincorporated EdU by day 6 (Figure 2F). By contrast, the pro-
apoptotic protein BIM, whichmediates CD8+ T cell death in toler-
ance models (Davey et al., 2002), was comparably expressed in
mutant and wild-type OT-I cells (Figure S2A). Paradoxically, the
pro-survival BCL2 protein was downregulated in Ndfip1 mutant
T cells (Figure S2B), but this likely reflects greater effector differ-
entiation (described later). However, when mutant and wild-type
OT-I cell death was analyzed with the cell viability dye 7AAD and
Annexin V (AxV), there was a small decrease in early apoptotic
(AxV+7AAD) mutant OT-I cells, with a corresponding increase
in AxV7AAD live cells (and no change in late apoptotic or
necrotic 7AAD+ cells) (Figure 2G). Thus, NDFIP1 restrains both
CD8+ T cell replication rate and survival in response to high tol-
erogen doses.
We next tested whether Ndfip1 mutant OT-I cells aberrantly
became effectors, because CD8+ T cell peripheral tolerance
checkpoints normally inhibit cytotoxic effector cell differentiation
by limiting cytolytic protease Granzyme B (GzmB) expression
and cytokine production (Hernandez et al., 2001; Parish et al.,
2009). In response to high-dose peptide, a higher percentage
and number of GzmB+ CD62L Ndfip1 mutant OT-I cells were
seen on day 6 (Figure 2H). To assess whether this translated
into increased target killing by mutant cells, we conducted an
in vivo cytotoxicity assay on day 6. After 4 hr, we observed signif-
icantly more killing by splenic mutant versus wild-type OT-I cells
(Figure 2I). Because the assay was saturated in the mutant con-
dition (i.e., all peptide-pulsed targets were killed), this likely un-
derestimates mutant OT-I cell killing. In contrast, mutant cells
did not exhibit elevated cytokine production at any time point
(Figure S2C). OT-I cells variably maintained the capacity to de-
granulate (as assessed by surface CD107a expression), but
mutant and wild-type degranulation was similar (Figure S2D).
Elevated GzmB+ CD62L Ndfip1 mutant OT-I cells were also
seen at low peptide doses, although this was less pronounced
than at high peptide doses (Figure S2E) and no GzmB+
CD62L mutant OT-I cells were seen in RIP-OVAhi mice not
treated with peptide (data not shown). Thus, in addition to
increased expansion, NDFIP1-deficient CD8+ T cells aberrantly
form cytolytic effectors.
Because naive precursor frequency can affect CD8+ T cell dif-
ferentiation, we next examined whetherNdfip1mutant OT-I cells
aberrantly expanded and differentiated at low precursor fre-
quencies. Although more variability was observed at lower pre-
cursor frequencies, we still observed augmented expansion
and effector differentiation of mutant OT-I cells (Figures S2F
and S2G), suggesting that the mutant phenotype is largely inde-
pendent of precursor frequency.
Ndfip1 Limits TCR Signaling in Anergic CD8+ T Cells
We next asked whether exaggerated effector cell formation in
Ndfip1-deficient OT-I cells was via the same mechanism as in
CD4+ T cells. In Ndfip1/ CD4+ T cells, exaggerated Th2
differentiation is accompanied by greater levels of the Th2
transcription factor JUNB, which is a direct target of ITCHcontrol mice (pooled B6 and RIP-OVAhi mice) (n = 7 mice per group from 2
experiments).
***p < 0.001.
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Figure 2. Ndfip1 Mutant OT-I Cells Resist
Tolerance to High Antigen Doses
(A) B6 mice were injected with 2 3 106 OT-I cells
that were a 50:50 mix of Ndfip1+/+ and Ndfip1kru/kru
cells and then peptide treated and analyzed.
(B–D) Representative plots (B) and pooled data (C
and D) showing the ratio (B and D) and number (C)
of Ndfip1+/+ (CD45.1/CD45.1) and Ndfip1kru/kru
(CD45.1/CD45.2) OT-I cells after low- and high-
dose OVA peptide treatment (n = 6–19 mice per
group from 3 to 5 experiments).
(E) Percentage of Ki67+ Ndfip1+/+ and Ndfip1kru/kru
OT-I cells after high-dose peptide treatment on the
indicated days (n = 7–10mice per group from 3 to 4
experiments). Histogram shows data at day 6.
(F) EdU incorporation into Ndfip1+/+ and
Ndfip1kru/kru OT-I cells at day 6 after high-dose
peptide treatment (n = 7–8 mice per group from 2
experiments). Histogram shows data at day 6.
(G) Percentages of live (7AADAxV), early
apoptotic (7AADAxV+), and late apoptotic/
necrotic (7AAD+) Ndfip1+/+ and Ndfip1kru/kru OT-I
cells at day 6 after high-dose peptide (n = 6 mice
per group from 2 experiments).
(H) Percentage and number of GzmB+ CD62L+
Ndfip1+/+ and Ndfip1kru/kru OT-I cells at days 3 and
6 after high-dose peptide (n = 8–9 mice per group
from 4 experiments). Contour plot shows data at
day 6.
(I) B6 mice given 2 3 106 Ndfip1+/+ or Ndfip1kru/kru
OT-I cells were treated with high-dose OVA pep-
tide or PBS as in (A). At day 6, mice (including
control untreated B6 mice) were injected with a
50:50 mix of OVA peptide-coated CTVhi and un-
treated CTVlo cytotoxic T lymphocyte (CTL) target
cells, and splenic target cell lysis was measured
after 4 hr. Representative histograms and the
percentage of lysis are shown (n = 8 mice per
group from 2 experiments, error bars are SEM).
*p < 0.05, **p < 0.01, ***p < 0.001.(Altin et al., 2014; Oliver et al., 2006). Ndfip1/ CD4+ T cells also
produce more IL-2 and express more of the high-affinity IL-2 re-
ceptor (CD25) (Ramos-Hernández et al., 2013). By contrast,
there was no increase in IL-2, CD25, or JUNB in NDFIP1-defi-
cient OT-I cells responding to high peptide doses (Figures
S2C, S3A, and S3B). Thus, the NDFIP1-mediated CD8+ T cell
checkpoint is distinct from the checkpoint mechanism in CD4+
T cells.
We next examined whether NDFIP1 restrains TCR signaling in
CD8+ T cells, because the ITCH ubiquitin ligase inhibits TCR
signaling during in vitro ionomycin-induced CD4+ T cell anergy
(Heissmeyer et al., 2004), and TCR-induced ERK phosphoryla-
tion is inhibited in CD8+ T cells exposed to high tolerogen doses
(Redmond et al., 2005). After in vitro peptide restimulation, 76%580 Cell Reports 24, 577–584, July 17, 2018of control OT-I cells from PBS-treated
mice phosphorylated ERK (denoted
ppERK; PBS group) (Figure 3A). By
contrast, on day 3, only 15% of OT-I cells
treated with high-dose peptide were
ppERK+ after restimulation, regardless ofNdfip1 genotype. However, on day 4, in vitro restimulation
induced ppERK in 30% of OT-I cells, with significantly more
ppERK+ Ndfip1-deficient versus wild-type cells (Figure 3A). By
day 6, ERK signaling inmutant andwild-type cells had recovered
comparably. Recovery of function upon antigen withdrawal
within peptide anergy models has been observed by others
(Pape et al., 1998; Redmond et al., 2005).
TCR-induced mTOR signaling is impaired during CD4+ T cell
anergy (Zheng et al., 2007), and this was seen in OT-I cells
exposed to 10 mg of OVA peptide. 79% of restimulated OT-I
cells from PBS-treated mice phosphorylated ribosomal protein
S6 (pS6), an mTOR target, compared to only 37% of wild-
type OT-I cells on day 3 (Figure 3B). Ndfip1-deficient OT-I
cells again had a partial rescue in signaling, with significantly
A 
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Figure 3. NDFIP1 Restrains OT-I TCR Signaling after High-Dose Peptide Treatment
(A–D) OT-I cells subjected to high-dose OVA peptide treatment in Figure 2 were analyzed for ppERK (A) and pS6 (B) upon 15 min in vitro peptide restimulation
(n = 7–11 mice per group from 3 experiments) or forward (C) and side (D) scatter (n = 8–16 mice per group from 4 experiments) at the indicated time points.
**p < 0.01, ***p < 0.001.greater pS6 responses at this time point and on days 4 and 6
(Figure 3B).
Because ERK and mTOR signaling promote anabolic growth,
we compared forward scatter as ameasure of cell size inNdfip1-
deficient and wild-type OT-I cells before restimulation. Forward
and side scatter were significantly increased in Ndfip1 mutant
versus wild-type OT-I cells on day 4 (Figures 3C and 3D). Thus,
an inability to fully dampen TCR signaling in Ndfip1 mutant
OT-I cells may explain their exaggerated expansion and effector
differentiation.
To test whether augmented mTOR signaling causes the
Ndfip1 mutant OT-I cell phenotype, mice containing peptidestimulated wild-type and mutant OT-I cells were treated with ra-
pamycin from days 3 to 5 of the experiment. Although rapamycin
treatment reduced overall OT-I expansion and effector differen-
tiation (Figures S3C and S3D), augmented expansion and differ-
entiation of mutant relative to wild-type OT-I cells was still
observed (Figures S3E and S3F). Thus, elevated mTOR signaling
alone cannot explain the mutant phenotype.
Ndfip1 Restrains CD8+ T Cell Expansion and Effector
Differentiation during Continuous Antigen Exposure
Ndfip1-deficient CD8+ T cells underwent exaggerated expan-
sion and effector differentiation after the last peptide injection.Cell Reports 24, 577–584, July 17, 2018 581
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Figure 4. NDFIP1 Controls OT-I Anergy to Sustained Antigen
(A) High-dose peptide anergy experiment conducted as in Figure 2, except
OVA peptide (or PBS) treatment was sustained.
(B–G) Ratios of WT to mutant cells (B), GzmB and CD62L expression (C),
ppERK (D), and pS6 (E) after in vitro peptide restimulation, and forward (F) and
side (G) scatter are shown (n = 10–11 mice per group from 2 experiments).
***p < 0.001.
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T cell checkpoint in the face of sustained antigen by continuing
the high-dose peptide injections for the duration of the experi-
ment (Figure 4A). Ndfip1mutant OT-I cells exposed to sustained
antigen still expanded to higher numbers than co-transferred
wild-type cells (Figure 4B) and formed more GzmB+ CD62L
effector cells (Figure 4C). As with transient peptide treatment,
the NDFIP1-deficient cells retained higher TCR-induced ppERK
and pS6 (Figures 4D and 4E) and displayed an increase in for-
ward and side scatter (Figures 4F and 4G).
Ndfip1 Does Not Limit CD8+ T Cell Expansion and
Differentiation during Infection
To test whether NDFIP1 also repressed effector T cell expansion
and differentiation during an acute infection, Ndfip1 mutant or
wild-type OT-I cells were transferred into B6 mice that were
then infected with Listeria monocytogenes, using a strain that
transgenically expresses OVA (Figure S4A). Wild-type and
mutant OT-I cell expansion was similar at day 10 post-infection
(Figure S4B). mTOR signaling promotes effector CD8+ T cell ter-
minal differentiation (Araki et al., 2009), but we did not see an in-
crease in terminal effectors (KLRG1hiCD127lo) or loss of memory
precursors (KLRG1loCD127hi) in mutant cells, suggesting no
functionally relevant increase in mTOR signaling (Figure S4C).
Thus, Ndfip1 loss does not influence effector CD8+ T cell differ-
entiation and expansion during Listeria infection.
To better delineate effector and memory differentiation of
Ndfip1/CD8+ T cells, we examined the response to acute lym-
phocytic choriomeningitis virus Armstrong strain (LCMV-Arm)
infection. To avoid bystander autoimmunity in Ndfip1kru/kru
mice, we used mice bearing a floxed Ndfip1 allele (Ndfip1f/f)
and a GranzymeB-cre (GzmB-cre) transgene. GzmB-cre mice
delete floxed alleles in activated effector CD8+ T cells during
LCMV infection but only minimally flox genes in activated CD4+
T cells (Rutishauser et al., 2009). Consistent with minimal gene
deletion in CD4+ T cells, no dermatitis or fatal autoimmune dis-
ease was seen in GzmB-cre+ Ndfip1f/f mice up to 3–4 months
of age, and unlike Ndfip1/ mice, there was no accumulation
of activated T cells in the blood of 8 week old mice (data not
shown). GzmB-cre+ Ndfip1f/f (conditional knockout, or cKO)
mice or GzmB-cre+ Ndfip1+/+ littermate (wild-type, or WT) con-
trols were infected with LCMV-Arm, and the CD8+ T cell
response was tracked in the blood to an early memory time point
(day 42), after which splenic memory T cell number, phenotype,
and function was assessed. There were no changes in expan-
sion, contraction, and persistence of tetramer+ CD8+ T cells
specific for the immunodominant LCMV GP33–41 or NP396–404
peptides in cKO versus WT mice (Figures S5A and S5B).
Although the proportion of KLRG1hi and KLRG1loCD127hi cells
was also unchanged at the peak of expansion (day 8), a
significant decrease in KLRG1loCD127hi cells was seen within
GP33–41 and (to a lesser extent) NP396–404-specific cells (Fig-
ure S5B) (data not shown), although accumulation of CD62Lhi
central memory cells was normal (Figure S5C). Similar trends
were observed within splenic memory cells (Figures S5D–S5F).
However, memory T cell function was unchanged. The same
number of interferon g (IFNg)-producing cells was recovered in
WT and cKO mice (Figure S5G), with no alteration in IFNg
produced per cell or proportions of IFNg+ tumor necrosis factor
a+ (TNF-a+) cells and IFNg+TNF-a+IL-2+ cells (Figure S5H).
Thus, Ndfip1 loss minimally affects the CD8+ T cell response to
an acute systemic infection.
DISCUSSION
In this study, we reveal a CD8+ T cell-intrinsic, highly context-
dependent NDFIP1-mediated tolerance checkpoint.Ndfip1 defi-
ciency dysregulates CD8+ T cells by a different mechanism than
in CD4+ T cells. Ndfip1/ CD4+ T cell hyper-proliferation is due
to elevated IL-2 production and an inability to exit the cell cycle
(Altin et al., 2014; Ramos-Hernández et al., 2013), and it is
accompanied by excessive IL-4 production and Th2 differentia-
tion due to JUNB accumulation (Oliver et al., 2006). By contrast,
IL-2 production and JUNB were not increased in Ndfip1-defi-
cient OT-I cells, and augmented expansion was via more rapid
proliferation and diminished death rather than cell-cycle exit
deficiencies. Elevated GzmB expression in Ndfip1-deficient
CD8+ T cells demonstrates that NDFIP1 can inhibit type 1 im-
mune responses, in contrast to CD4+ T cells, in which NDFIP1
loss has little effect on Th1 differentiation (Layman et al.,
2017b; Oliver et al., 2006).
The primary biochemical effect of NDFIP1 deficiency in high-
zone CD8+ T cell tolerancewas partial recovery of TCR signaling.
Other mechanisms, such as the ubiquitin ligase CBLB (Heiss-
meyer et al., 2004; Jeon et al., 2004) or diacylglycerol kinase
alpha (Olenchock et al., 2006), must also contribute to TCR
desensitization, because signaling in NDFIP1-deficient CD8+
T cells remained lower than in non-tolerized control T cells.
NDFIP1 may directly target mTOR signaling pathway compo-
nents, and increased mTOR signaling was proposed to augment
Ndfip1/ regulatory T cell (Treg) proliferation and differentiation
(Layman et al., 2017a); however, our data suggest that elevated
mTOR signaling alone cannot explain the mutant CD8+ T cell
phenotype. Our data also do not rule out a role for pathways
beyond partially rescued TCR signaling in the Ndfip1 mutant
cell phenotype, and further work is required to pinpoint the
mechanism.
Studies on CD8+ T cell checkpoints largely focus on exhaus-
tion, in which established effector cells lose inflammatory func-
tion when chronically stimulated. By contrast, in vivo tolerance
checkpoints that regulate initial CD8+ T cell activation are poorly
defined in molecular terms. Our findings provide evidence that
molecularly distinct tolerance pathways operate in the context
of high and low tolerogen doses. Because high and low antigen
doses favor anergy and deletion, respectively (Redmond et al.,
2005), and only high-zone tolerance depends on NDFIP1, these
data imply that deletion and anergy are molecularly separable
states. This difference may be due to the 6 day delay in Ndfip1
mutant OT-I cell phenotype; responding cells may die in deletion
models before a phenotype can manifest. Alternatively, because
Ndfip1 is TCR induced, it may only enforce tolerance during
strong TCR engagement. However, there may be a delay in the
kinetics of peripheral deletion that was missed in our study.
Moreover, because a hallmark of anergy is cell persistence, the
long-term persistence of Ndfip1-deficient anergic cells needs
to be examined.The NDFIP1-mediated tolerance checkpoint may maintain
CD8+ T cell tolerance to abundant environmental antigens
(e.g., commensal and food antigens), fetal antigens once the
fetus has increased in mass, or abundant peripheral self-
antigens not efficiently expressed in the thymus. Thus, dysre-
gulated CD8+ T cell tolerance could contribute to the
autoimmune and inflammatory diseases seen in patients with
NDFIP1 polymorphisms. NDFIP1 may also limit CD8+ T cell
priming against high-burden tumors and could have utility in
cancer immunotherapy. Finally, although Ndfip1 loss has little
effect on the effector T cell response to acute infection, our
data do not rule out a role for Ndfip1 in effector CD8+ T cell
exhaustion during chronic stimulation within tumors or persis-
tent viral infection. Future work is needed to evaluate these
possibilities.EXPERIMENTAL PROCEDURES
Mice
C57BL/6, OT-I, B6.129S7-Rag1tm1Mom/J (Rag1/), and B6.SJL-PtprcaPep3b/
BoyJ (CD45.1) mice were purchased from the Australian Phenomics Facility,
Australian National University (ANU), Australia. RIP-OVAhi (Kurts et al., 1998),
Ndfip1kru/kru (Altin et al., 2014), GzmB-cre (Jacob and Baltimore, 1999),
and Ndfip1f/f (Howitt et al., 2012) mice have been previously described. All
animal work was in accordance with protocols approved by the ANU
Animal Experimentation Ethics Committee and current guidelines from the
Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes.
Flow Cytometric Analysis
Cell suspensions were stained in PBS containing 2.5% fetal calf serum and
0.1% azide. Intracellular staining was conducted using the Foxp3 Transcrip-
tion Factor Staining Buffer Set (eBioscience) according to manufacturer’s in-
structions. Samples were collected on a BD LSRII, Fortessa, or X20 flow
cytometer (BD Biosciences), with data analyzed using FlowJo Software
(Tree Star).
Statistical Analysis
Data analysis was conducted using Prism Software (GraphPad). Data were
analyzed using paired or unpaired t tests or two-way ANOVA with a Bonferroni
post-test (Figures S5A–S5C).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.06.060.
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